Endurance RP: Excellent Positive Results from Phase 3 Randomised Clinical Trial of Fortacin(TM)/Senstend(TM) in China Endurance RP Limited Apr 17, 2023 22:29 HKT/SGT Read More
HanchorBio Announces US IND Clearance for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies HanchorBio Inc Apr 17, 2023 19:30 HKT/SGT Read More
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore Essex Bio-Technology Limited Apr 14, 2023 17:18 HKT/SGT Read More
Responding to the Need for Accelerated Nursing Credentials Verification, CGFNS and NCSBN Step Up Collaboration to Address Gaps and Improve Efficiencies CGFNS International Apr 12, 2023 19:30 HKT/SGT Read More
Responding to the Need for Accelerated Nursing Credentials Verification, CGFNS and NCSBN Step Up Collaboration to Address Gaps and Improve Efficiencies CGFNS International Apr 12, 2023 19:30 HKT/SGT Read More
Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC Absorbable Dressing in Mainland China Essex Bio-Technology Limited Apr 11, 2023 12:58 HKT/SGT Read More
TrialWire Patient Recruitment Platform Launches AI Pre-recruit to Cut Recruitment Time by 50% TrialWire Apr 11, 2023 08:00 HKT/SGT Read More
Eisai Completes a Major Renovation of Tsukuba Research Laboratories Eisai Apr 06, 2023 17:32 HKT/SGT Read More
Life Science Incubator Signs MOU with a strategic anchor tenant for its planned Brisbane Co-Working Laboratory Space Project AcroMeta Group Limited Apr 06, 2023 14:00 HKT/SGT Read More
Moolec Science Achieves USDA-APHIS Regulatory Status Review Clearance for Molecular Farming Product Moolec Science SA Apr 05, 2023 18:00 HKT/SGT Read More
Moolec Science Achieves USDA-APHIS Regulatory Status Review Clearance for Molecular Farming Product Moolec Science SA Apr 05, 2023 18:00 HKT/SGT Read More
BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies BioMed X Institute Apr 04, 2023 17:00 HKT/SGT Read More
BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies BioMed X Institute Apr 04, 2023 17:00 HKT/SGT Read More
Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal Eisai Apr 04, 2023 12:23 HKT/SGT Read More